Skip to search formSkip to main contentSkip to account menu

MDM2 Inhibitor DS-3032b

Known as: DS-3032b, HDM2 Inhibitor DS-3032b 
An orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, MDM2 inhibitor DS… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b
Development of MDM2 inhibitors enabled successful induction of p53-mediated apoptosis in tumor cells without a risk of DNA damage… 
2015
2015
Abstract B5: Preclinical characterization of a novel orally-available MDM2 inhibitor DS-3032b: Anti-tumor profile and predictive biomarkers for sensitivity
The p53 protein exerts its tumor suppressor function by inducing cell cycle arrest, apoptosis, or senescence in cells under… 
2015
2015
Abstract B27: A phase I dose escalation study of the MDM2 inhibitor DS-3032b in patients with advanced solid tumors and lymphomas
Background: Reactivation of the tumor suppressor functions of p53 by targeting its negative regulator mdm2 represents an… 
2015
2015
Abstract B1: Gene expression and TP53 mutation analysis predict sensitivity of leukemia cells to MDM2 inhibition by DS-3032b
Background: MDM2 overexpression, by preventing p53 activation, contributes to the growth and development of a variety of solid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)